Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Conditions

HCC - Hepatocellular Carcinoma · Conversion Therapy

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Huikai Li, Prof.) · tjchlhk@126.com · 18622228639

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States

Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer

Hepatocellular Carcinoma · Gastrointestinal Cancer Metastatic · Neuroendocrine Tumors

Abroad (travel likely)RecruitingPHASE1, PHASE2

Palo Alto, United States · Philadelphia, United States

Evaluation of Stereotactic Body Radiotherapy as a Bridge Therapy for Hepatocellular Carcinoma Patients Enlisted for Liver Transplantation

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE2

Paris, France